Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Daniel E. Castellano"'
Autor:
Xavier García-del-Muro, Ignacio Durán, Jose Luis Perez-Gracia, Miguel Ángel Climent, Begoña Mellado, Juan A. Virizuela, Daniel E. Castellano, Aranzazu González del Alba, Iciar García Carbonero, Carlos Álvarez-Fernández, Jesús García-Donas, Marta Gil-Martin, Alvaro-González Hernández
Publikováno v:
Clinical Genitourinary Cancer. 20:388.e1-388.e10
The therapeutic repertoire available for advanced renal cell carcinoma (RCC), including tyrosine kinase inhibitors (TKIs) and immunotherapy, required for molecular biomarkers for response.This was a phase I to II trial on the combination of pazopanib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6721d24dad1b0f3a742eb24d8dfcdaec
https://doi.org/10.1016/j.clgc.2022.03.008
https://doi.org/10.1016/j.clgc.2022.03.008
Autor:
Valentina Boni, Barbara Pistilli, Irene Brana, Geoffrey Shapiro, Jose Manuel Manuel Trigo Perez, Victor Moreno, Daniel E. Castellano, Cristian Marcelo Fernandez, Carmen Maria Kahatt, Vicente Alfaro, Mariano Siguero, Ali Hassan Zeaiter, Federico Longo, Khalil Zaman, Antonio Antón Torres, Alfredo Paredes Lario, Gerardo Huidobro Vence, Vivek Subbiah
Publikováno v:
Journal of Clinical Oncology. 40:1092-1092
1092 Background: Lurbinectedin (L) is a selective inhibitor of oncogenic transcription that leads to cell apoptosis and shows antitumor activity against homologous recombination repair-deficient cell lines. A previous phase II study (Cruz et al. JCO
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bd1390a8e1933ac0d1e01ec5ec125910
https://doi.org/10.1200/jco.2022.40.16_suppl.1092
https://doi.org/10.1200/jco.2022.40.16_suppl.1092
Autor:
Rafael Morales-Barrera, Daniel E. Castellano, Peter H. O'Donnell, Petros Grivas, Jacqueline Vuky, Thomas Powles, Kylea R. Potvin, Susanna Y. Cheng, Eli Rosenbaum, Noah M. Hahn, Daniel Keizman, Fausto Roila, Jose Luis Perez-Gracia, Elizabeth R. Plimack, Ronald De Wit, Jin Zhi Xu, Kentaro Imai, Haojie Li, Josephine M. Norquist, Joaquim Bellmunt
Publikováno v:
Journal of Clinical Oncology. 40:4561-4561
4561 Background: Frontline cisplatin-based chemotherapy improves survival in patients (pts) with UC, but ̃50% are cisplatin-ineligible owing to poor performance status or comorbidity. The definition of platinum ineligibility is not standardized; hen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::03684d61419b5114fede9b528ab7ad85
https://doi.org/10.1200/jco.2022.40.16_suppl.4561
https://doi.org/10.1200/jco.2022.40.16_suppl.4561
Autor:
Jonathan E. Rosenberg, Thomas Powles, Guru P. Sonpavde, Yohann Loriot, Ignacio Duran, Jae-Lyun Lee, Nobuaki Matsubara, Christof Vulsteke, Daniel E. Castellano, Ronac Mamtani, Chunzhang Wu, Maria Matsangou, Mary S. Campbell, Daniel P. Petrylak
Publikováno v:
Journal of Clinical Oncology. 40:4516-4516
4516 Background: Enfortumab vedotin (EV), an antibody-drug conjugate directed against Nectin-4, demonstrated longer overall survival (OS) and progression-free survival (PFS) in the confirmatory phase 3, randomized, open-label EV-301 trial at the pres
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7dc915c0592da9cea9f5c28bb1f217aa
https://doi.org/10.1200/jco.2022.40.16_suppl.4516
https://doi.org/10.1200/jco.2022.40.16_suppl.4516
Autor:
Alvaro Pinto, Lucía Trilla-Fuertes, Jesus Miranda Poma, Naveen Vasudev, Eugenia García-Fernández, Rocio Lopez Vacas, Natalia Miranda, Michelle Wilson, Elena López-Camacho, Ana Pertejo, Maria Isabel Lumbreras-Herrera, Joanne C Brown, Andrea Zapater-Moros, Guillermo De Velasco, Daniel E. Castellano, María Pilar González-Peramato, Enrique Espinosa, Rosamonde Banks, Juan Angel Fresno-Vara, Angelo Gámez-Pozo
Publikováno v:
Journal of Clinical Oncology. 40:e16519-e16519
e16519 Background: Prognosis of localized clear cell renal cell carcinoma (ccRCC) patients is estimated by nomograms based on clinico-pathological factors. However, clinical guidelines do not recommend their use. Recently, pembrolizumab has demonstra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2f97c803eb5eb3a8ea0830f6cbc93819
https://doi.org/10.1200/jco.2022.40.16_suppl.e16519
https://doi.org/10.1200/jco.2022.40.16_suppl.e16519
Autor:
Jonathan E. Rosenberg, Se Hoon Park, Tu V. Dao, Daniel E. Castellano, Jian-Ri Li, Som Mukherjee, Kathryn Howells, Hannah Dry, Mark C. Lanasa, Ross Stewart, Dean F. Bajorin
Publikováno v:
Journal of Clinical Oncology. 40:437-437
437 Background: The prognosis for patients (pts) with advanced UC remains poor, particularly for those unable to tolerate platinum-based chemotherapy. Defects in DNA damage repair (e.g., mutations in homologous recombination repair [HRR] genes) are c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::19009f2790938bdcb80c6a7e6c24a094
https://doi.org/10.1200/jco.2022.40.6_suppl.437
https://doi.org/10.1200/jco.2022.40.6_suppl.437
Autor:
Xavier Garcia del Muro, François Riva, M. Andres Cuellar, Pablo Maroto-Rey, Daniel E. Castellano, Patrizia Giannatempo, Miguel Angel A. Climent Duran, Andrea Necchi, Begoña Pérez-Valderrama, Alfonso Gomez De Liano Lista, Carmen Garcias-Espana, Javier Puente, Silverio Ros, Carmen Santander, Cristina Masini, Marta Martínez de Falcon, Almudena Garcia, Miguel Sampayo-Cordero, Andrea Malfettone, David Paez
Publikováno v:
Journal of Clinical Oncology. 40:TPS8-TPS8
TPS8 Background: PSqCC is a rare tumor with poor prognosis and limited therapeutic options. The current standard of care for advanced disease has been palliative platinum-based chemotherapy, with only marginal survival benefit. Recent data has shown
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::242ef980d16987652aedb89b50b78b55
https://doi.org/10.1200/jco.2022.40.6_suppl.tps8
https://doi.org/10.1200/jco.2022.40.6_suppl.tps8
Autor:
Peter H. O'Donnell, Arjun Vasant Balar, Daniel E. Castellano, Ronald De Wit, David J. Vaughn, Thomas Powles, Jacqueline Vuky, Jae-Lyun Lee, Yves Fradet, Joaquim Bellmunt, Lawrence Fong, Daniel P. Petrylak, Winald R. Gerritsen, David I. Quinn, Stephane Culine, Dean F. Bajorin, Jin Zhi Xu, Kentaro Imai, Blanca Homet Moreno, Petros Grivas
Publikováno v:
Journal of Clinical Oncology. 40:516-516
516 Background: Pembro showed antitumor activity in 1L and 2L for pts with UC in the single-arm, phase 2 KEYNOTE-052 study (NCT02335424) and the randomized phase 3 KEYNOTE-045 (NCT02256436) study, respectively. This post hoc exploratory analysis eval
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bafbe209abdb3ecbfd414e1a37e58086
https://doi.org/10.1200/jco.2022.40.6_suppl.516
https://doi.org/10.1200/jco.2022.40.6_suppl.516
Autor:
Daniel E. Castellano, Arjun Vasant Balar, Peter H. O'Donnell, Petros Grivas, David J. Vaughn, Thomas Powles, Jacqueline Vuky, Jae-Lyun Lee, Yves Fradet, Joaquim Bellmunt, Miguel Ángel Climent, Nicholas J. Vogelzang, Elizabeth R. Plimack, Howard Gurney, Noah M. Hahn, Cora N. Sternberg, Jin Zhi Xu, Kentaro Imai, Blanca Homet Moreno, Ronald De Wit
Publikováno v:
Journal of Clinical Oncology. 40:512-512
512 Background: Pembrolizumab (pembro) has shown efficacy in advanced/unresectable and metastatic UC (mUC). There is interest in determining whether pts should be treated subsequently with checkpoint inhibitors such as anti–PD-1 therapy if mUC resp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e5a3ee2c3016a5da8b2884bc7ce9eaf2
https://doi.org/10.1200/jco.2022.40.6_suppl.512
https://doi.org/10.1200/jco.2022.40.6_suppl.512
Autor:
Tibor Csoszi, Thomas Powles, Ajjai Shivaram Alva, Daniel E. Castellano, Mustafa Ozguroglu, Peter H. O'Donnell, Yohann Loriot, Noah M. Hahn, Aude Flechon, Alejo Rodriguez-Vida, Ronald De Wit, Susanna Y. Cheng, Stephane Oudard, Christof Vulsteke, Evan Y. Yu, Jianxin Lin, Kentaro Imai, Blanca Homet Moreno, Arjun Vasant Balar, Petros Grivas
Publikováno v:
Journal of Clinical Oncology. 40:521-521
521 Background: First-line treatment with pembrolizumab (pembro) monotherapy has shown durable clinical activity in selected patients (pts) with advanced/unresectable or metastatic urothelial carcinoma (UC). In a pooled population of pts with advance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3e2743265a036f0dd28c5651f441caa1
https://doi.org/10.1200/jco.2022.40.6_suppl.521
https://doi.org/10.1200/jco.2022.40.6_suppl.521